Influence of chronic hepatic failure on disposition kinetics of valproate excretion through a phase II reaction in rats treated with carbon tetrachloride

The influence of chronic hepatic failure on the disposition kinetics of valproate (VPA) excretion via a phase II reaction was examined in rats treated with carbon tetrachloride (1.0 mg/kg, s.c., 3 times a week) for 2 or 3 months. There was no significant difference in the plasma concentration‐time courses of VPA among the control and two treated groups up to 120 min after i.v. administration of VPA (75 mg/kg), but subsequently the plasma concentrations of the treated groups declined significantly below the control levels. Expression of Mrp2 mRNA in the liver of the treated groups was significantly lower than in the control group; conversely that in the kidney was significantly higher. The enzyme activity of UGTs in the liver of the treated groups decreased significantly, but UGT1A8 mRNA expression in the duodenum was increased about 3‐fold. Cumulative excretion of VPA glucuronide (VPA‐G) in bile of the treated groups was reduced significantly, while that in urine was markedly increased. In conclusion, the area under the VPA plasma concentration‐time curve was decreased significantly in rats with chronic hepatic failure owing to increased excretion of VPA‐G via the kidney as a result of induction of Mrp2, and inhibition of enterohepatic circulation of VPA‐G. Copyright © 2007 John Wiley & Sons, Ltd.

[1]  K. Miyamoto,et al.  Development of dosage design of hepatic metabolizing drugs using serum albumin level in chronic hepatic failure. , 2006, Biological & pharmaceutical bulletin.

[2]  K. Miyamoto,et al.  Serum aminotransferase activity as a predictor for estimation of total clearance of hepatically metabolized drugs in rats with acute hepatic failure. , 2006, Biological & pharmaceutical bulletin.

[3]  T. Daidoji,et al.  UDP-GLUCURONOSYLTRANSFERASE ISOFORMS CATALYZING GLUCURONIDATION OF HYDROXY-POLYCHLORINATED BIPHENYLS IN RAT , 2005, Drug Metabolism and Disposition.

[4]  Kiyoshi Yamaoka,et al.  Statistical moments in pharmacokinetics , 1978, Journal of Pharmacokinetics and Biopharmaceutics.

[5]  Y. Sugiyama,et al.  Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[6]  R. Dickinson,et al.  Abolition of Valproate-Derived Choleresis in the Mrp2 Transporter-Deficient Rat , 2004, Journal of Pharmacology and Experimental Therapeutics.

[7]  K. Miyamoto,et al.  Serum aminotransferase activity as a predictor of clearance of drugs metabolized by CYP isoforms in rats with acute hepatic failure induced by carbon tetrachloride. , 2004, International journal of pharmaceutics.

[8]  B. Burchell,et al.  The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. , 2003, Biochemical pharmacology.

[9]  Y. Leung,et al.  Induction of UDP-glucuronosyltransferase 1A8 mRNA by 3-methylcholanthene in rat hepatoma cells. , 2002, Biochemical pharmacology.

[10]  Y. Artur,et al.  Induction of cytochrome P450 and/or detoxication enzymes by various extracts of rosemary: description of specific patterns. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[11]  C. Strassburg,et al.  Distribution and inducibility by 3-methylcholanthrene of family 1 UDP-glucuronosyltransferases in the rat gastrointestinal tract. , 2000, Archives of biochemistry and biophysics.

[12]  H. Naganuma,et al.  Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[13]  T. Hasegawa,et al.  Possible Mechanism by Which the Carbapenem Antibiotic Panipenem Decreases the Concentration of Valproic Acid in Plasma in Rats , 1998, Antimicrobial Agents and Chemotherapy.

[14]  D W Nebert,et al.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.

[15]  A. Kerremans Cytochrome P450 isoenzymes--importance for the internist. , 1996, The Netherlands journal of medicine.

[16]  K. Ohya,et al.  Osteoporosis‐like Changes in Walker Carcinoma 256‐Bearing Rats, Not Accompanied with Hypercalcemia or Parathyroid Hormone‐related Protein Production , 1995, Japanese journal of cancer research : Gann.

[17]  F. Meyer,et al.  Sensitive capillary gas chromatographic-mass spectrometric method for the therapeutic drug monitoring of valproic acid and seven of its metabolites in human serum. Application of the assay for a group of pediatric epileptics. , 1994, Journal of chromatography. B, Biomedical applications.

[18]  F. Guengerich,et al.  Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. , 1991, The Journal of pharmacology and experimental therapeutics.

[19]  G. Zaccara,et al.  Clinical Pharmacokinetics of Valproic Acid — 1988 , 1988, Clinical pharmacokinetics.

[20]  R. Gugler,et al.  Clinical Pharmacokinetics of Valproic Acid , 1980, Clinical pharmacokinetics.

[21]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.